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Abstract
Background: The transfer of patients to and from the Intensive Care Unit (ICU) is prone to medication errors. The
aim of the present study is to determine whether the number of medication errors at ICU admission and discharge
and the associated potential harm and costs are reduced by using the Transfer ICU and Medication reconciliation
(TIM) program.
Methods: This prospective 8-month observational study with a pre- and post-design will assess the effects of
the TIM program compared with usual care in two Dutch hospitals. Patients will be included if they are using at
least one drug before hospital admission and will stay in the ICU for at least 24 h. They are excluded if they are
transferred to another hospital, admitted and discharged in the same weekend or unable to communicate in
Dutch or English.
In the TIM program, a clinical pharmacist reconciles patient’s medication history within 24 h after ICU admission,
resulting in a “best possible” medication history and presents it to the ICU doctor. At ICU discharge the clinical
pharmacist reconciles the prescribed ICU medication and the medication history with the ICU doctor, resulting
in an ICU discharge medication list with medication prescription recommendations for the general ward doctor.
Primary outcome measures are the proportions of patients with one or more medication transfer errors 24 h
after ICU admission and 24 h after ICU discharge. Secondary outcome measures are the proportion of patients
with potential adverse drug events, the severity of potential adverse drug events and the associated costs.
For the primary outcome relative risks and 95% confidence intervals will be calculated.
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Discussion: Strengths of this study are the tailor-made design of the TIM program and two participating
hospitals. This study also has some limitations: A potential selection bias since this program is not performed
during the weekends, collecting of potential rather than actual adverse drug events and finally a relatively short
study period.
Nevertheless, the findings of this study will provide valuable information on a crucial safety intervention in the ICU.
Trial registration: Dutch trial register: NTR4159, 5 September 2013
Keywords: Medication reconciliation, Medication error, Intensive care unit, Medication transfer, Clinical pharmacist,
Adverse drug event
Background
Patients in the intensive care unit (ICU) are more likely
to experience medication errors than other hospitalized
patients, since the chance of errors in an ICU setting is
high due to the high intensity of treatment in patients
with a critical illness [1, 2]. Medication errors can induce
adverse events and are associated with substantial costs
[3–10]. It has been demonstrated that chronic medica-
tion used by patients before admission to the ICU is
often unintentionally discontinued after the ICU stay
[11]. Because of the critical illness, non-vital medication
is often temporarily withheld. However when the patient
improves, the restart of this medication is easily forgot-
ten. On the other hand, drug therapy initiated for short-
term use in the ICU can be inadvertently continued after
ICU discharge. For example, several studies have dem-
onstrated that gastric acid-inhibitory drugs are fre-
quently continued inappropriately after discharge from
the ICU [12–14].
On regular wards, many Dutch hospitals use comput-
erized physician order entry systems with clinical deci-
sion support (CPOE/CDS). In general, these CPOE/CDS
systems cannot offer supporting systems for patient
monitoring required at ICUs. Therefore most ICUs in
the Netherlands do not use the general CPOE/CDS sys-
tem. Instead, they use a so-called Patient Data Monitor-
ing System (PDMS). However, these systems mostly lack
clinical decision support for prescribing and monitoring
medication. Besides, the use of two different systems
poses an additional threat to safe medication transfer to
and from the ICU.
Various interventions have been studied to reduce
medication errors on the ICU. A systematic review by
Manias et al. identified eight types of interventions:
implementation of CPOE, changes in working schedules,
intravenous systems, modes of education, medication
reconciliation, pharmacist involvement, protocols an
guidelines and support systems for clinical decision
making. Only four of these interventions demonstrated
reduced medication errors post-intervention, one of
which was medication reconciliation at ICU admission
[15]. Besides, a small number of studies suggest that that
the incidence of medication errors during and after
hospitalization can be reduced even further by additional
medication reconciliation at ICU discharge [16–18].
However, the effect of medication reconciliation after
ICU stay is not well described in the literature. The few
available studies suffer from one or more of the following
limitations: (1) small sample size; (2) failure to differenti-
ate between intentional and unintentional discrepancies
and (3) lack of assessment of potential clinical impact
and/or severity of discrepancies. Besides, it is not known
how patient safety will be affected by a combined admis-
sion and discharge medication reconciliation program in
the ICU.
In the present study, we hypothesize that continuity of
care will be improved and medication errors and patient
harm will be reduced if medication is reconciled during
both ICU transfers by a pharmacist in close collabor-
ation with the intensive care doctors and the ICU staff.
To test this hypothesis, we designed the TIM (Transfer
ICU and Medication reconciliation) program, which
consists of medication reconciliation by a pharmacist at
ICU admission and at ICU discharge.
Methods/Design
Aim of the study
The aim of this study is to determine the effect of the
TIM program on the number of medication transfer
errors (MTEs) at admission to and at discharge from the
ICU. Furthermore, we will investigate the effect of the
program on the number of potential adverse drug events
and their severity, and finally we will estimate the cost-
effectiveness of this program.
Design
A prospective 8-month observational study with a be-
fore and after design will be carried out at Haga
Teaching Hospital in The Hague (650 bed general
teaching hospital with 18 ICU beds; 1500 ICU admis-
sions a year) and Erasmus Medical Center in Rotterdam
(University Hospital, 1320 beds and 32 ICU beds; 1800
ICU admissions a year). Both hospitals are located in
the Netherlands.
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The study consists of three periods: first, a pre-
intervention period of 14 weeks during which patients
will be included who receive usual care; second, a period
of 4 weeks during which the TIM intervention program
will be implemented, and finally, a post intervention
period of 14 weeks during which patients will be in-
cluded in the TIM program (Fig. 1).
Study population
All patients admitted to the ICU during the study period
are eligible to participate in this study if they use at least
one drug at home and if the ICU length of stay exceeds
24 h. An ICU discharge and readmission within 24 h is
counted as one inclusion. Patients who die during the
ICU stay are included in the admission part of the study.
Readmissions to the ICU are also included.
Exclusion criteria are transfer to another hospital, both
admission and discharge within the same weekend
(Friday 17:00 until Monday 8:30) and patient’s inability
to be counseled in Dutch or English.
Study procedures
Usual care at ICU admission (pre-intervention period)
At ICU admission the ICU doctors determine pre-
admission medication. In this process, they rely on the
data from the previous ward (if applicable), the patient’s
general practitioner, relatives or previous hospital re-
cords (e.g. discharge letters, patient charts). Occasion-
ally, a faxed medication list is available from the
community pharmacy, but there is no standard proced-
ure for the ICU doctor to obtain medication lists from
the community pharmacy. Hence, ICU doctors do not
structurally perform medication reconciliation. The
admitting doctor registers pre-admission medication in
the PDMS system (Haga) or HIS (Hospital Information
System) (Erasmus MC) and only transcribes the medication
that is to be continued during the ICU stay into the
PDMS/CPOE
In Erasmus MC a dedicated ICU hospital pharmacist
reviews the prescribed medication on the ICU on a daily
basis during patient rounds. In Haga Teaching Hospital,
twice a week, one out of a team of 4 trained ICU hos-
pital pharmacists reviews prescribed medication and at-
tends the patient rounds on the ICU. In both hospitals,
the hospital pharmacists rely on the information about
pre-admission medication available in the PDMS and do
not obtain a medication list from the community phar-
macy, nor do they reconcile pre-admission medication
with the patient.
Usual care at ICU discharge
An ICU doctor writes an ICU discharge letter, which is
screened, verified and authorized by an intensivist.
Combined with a nurse discharge letter, this discharge
letter is sent to the admitting ward at the moment of pa-
tient transfer.
In Haga Teaching Hospital, the discharge letter contains
information about the registered pre-admission medica-
tion, the medication in use at discharge from the ICU and
suggestions about medication use after discharge (i.e.:
“Restart pre-admission medication”). In Erasmus MC, the
letter contains information about medication in use at
discharge and sometimes suggestions for medication use
after discharge.
After transfer, the doctor of the admitting ward has to
transcribe medication orders from the discharge letter to
the hospital CPOE/CDS. At the same time, doctors in
the Haga Teaching Hospital have to stop medication
registered in the CPOE/CDS that the patient is no lon-
ger required to take after ICU discharge, since the
CPOE/CDS system in this hospital does not automatic-
ally stop prescribed medication when the patient is
admitted to the ICU. By contrast, the CPOE/CDS system
Fig. 1 Study flow chart of the TIM program and defined outcomes. ICU = intensive care unit, MTE = medication transfer error, pADE = potential
adverse drug event, TIM = Transfer ICU and Medication reconciliation program
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in Erasmus MC stops all medication at admission to the
ICU, which urges the doctor to prescribe all medication
needed after the ICU transfer.
TIM program, the intervention
The TIM program consists of medication reconciliation
at ICU admission and at ICU discharge. In both inter-
vention hospitals, the program will be carried out by two
pharmacists. The pharmacists in Erasmus MC will be
supported by pharmacy students, who, after a training
period of several weeks, will be able to collect the medi-
cation lists and to interview the patients or their rela-
tives about each patient’s pre-admission medication.
TIM program at ICU admission
First, permission for reconciliation is obtained from the
patients or their relatives. Next, the pharmacist compiles
a best possible medication history (BPMH) as described
below in the section “the gold standard medication lists”.
In case of an internal transfer, the BPMH will also
include the pre-admission medication transcribed or
omitted at the previous ward.
Next, the pharmacist transfers the BPMH to the
PDMS system (Haga) or HIS (Erasmus MC) and pre-
sents the BPMH to the ICU doctor responsible for the
patient. If the pharmacist notices an inexplicable dis-
crepancy between pre-admission medication and medi-
cation prescribed on the ICU, he or she will discuss this
with the ICU doctor, enabling correction of unintended
omissions or other mistakes in the ICU prescriptions. Fi-
nally, the pharmacist in Haga Teaching Hospital stops
the patient’s medication in the CPOE/CDS system used
on the wards, which is done automatically in the HIS
system of Erasmus MC when the patient is admitted to
the ICU.
TIM program at ICU discharge
When a patient is discharged from the ICU, the pharma-
cist makes a discharge medication summary. This medi-
cation summary contains an overview of medications on
the patient’s BPMH combined with all the medication
the patient uses in the ICU at the moment of discharge.
For each drug, the ICU doctor is given a series of op-
tions of recommendations (i.e.: restart, stop, continue),
making it easier for the ICU doctor to provide clear
prescription suggestions to the doctor of the general
ward. The ICU pharmacist reconciles this medication list
with the ICU doctor. During this reconciliation, special
attention is paid to temporarily withheld medication that
should be restarted and to temporary ICU medication
that should be stopped. After this reconciliation, the
pharmacist amends the medication list to establish the
Best Possible ICU Medication Discharge List (BPMDL-
ICU) (example in Fig. 2). Once the doctor has approved
the BPMDL-ICU, it is combined with the discharge let-
ter of the ICU and sent to the doctor of the regular ward
at the moment of patient transfer.
In Erasmus MC, the pharmacist pre-registers the
BPMDL-ICU in the CPOE/CDS system, so the ward
doctor merely has to authorize this pre-registered medi-
cation list. Since pre-registration is not possible in the
CPOE/CDS system of Haga Teaching Hospital, here the
medication on admission is registered in the outpatient
CPOE/CDS system, from where the ward doctor can
easily transcribe this medication list to the inpatient
CPOE/CDS system.
The study procedures are summarized in Fig. 3.
The gold standard medication lists
In order to detect MTEs, we defined a gold standard
against which the actual prescribed medications are
compared.
ICU admission
The gold standard is defined as the Best Possible
Medication History (BPMH), which includes name, dos-
age, frequency, and route of all medication taken by a
particular patient. The BPMH is created as follows: a
pre-admission medication list is collected from the com-
munity pharmacy, which is combined with other avail-
able information about the patient’s medication, such as
a letter from the Emergency department (if applicable),
medication used in the general ward or medication lists
from the operating room (OR) (if applicable). This medi-
cation list is verified by means of an interview with the
patient and/or a relative, which will result in a BPMH.
ICU discharge
The gold standard is defined as the Best Possible
General Ward Medication List 24 h after the ICU
discharge (BPML-GW24). The BPML-GW24 includes
name, dosage, frequency, and route of all medication
that should ideally be prescribed within 24 h after ICU
discharge. This list is based on the BPMH, on information
found in the PDMS or the HIS of the ICU, on medication
prescribed in the CPOE/CDS and, whenever neces-
sary, on interviewing the ward doctor afterwards.
Collection of medication lists
Pre-intervention phase
For each included patient discharged from the ICU
for at least 24 h, a pharmacist generates a BPMH
and a BPML-GW-24 in order to trace medication
transfer errors.
Post-intervention phase
The pharmacist generates a BPMH for patients newly
admitted to the ICU and the Best Possible ICU Medication
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Discharge List (BPMDL-ICU) for patients planned to be
discharged. One day past ICU discharge, a medication chart
of current medication in the CPOE/CDS will be printed
and a BPML-GW24 will be compiled.
Outcome measures
Figure 1 presents a summary of outcome measures.
The primary outcome measures of this study are the
proportion of patients with one or more MTEs at
Fig. 2 Example of BPMDL-ICU. BPMDL-ICU = best possible ICU medication discharge list. N.B. This is a fictitious example, patient and doctor
names are imaginary
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admission to the ICU and the proportion of patients
with one or more MTEs after discharge from the ICU.
An MTE at admission is defined as an unintentional
discrepancy between BPMH and medication prescribed
within 24 h after admission to the ICU.
An MTE at discharge is defined as an unintentional
discrepancy between the BPML-GW24 and the medica-
tion chart of the patient within 24 h after discharge.
Whether a discrepancy at admission is unintentional
or not is based on information documented in the
PDMS, the ICU standards of care and the ICU pharma-
cist’s interpretation of the situation (see Fig. 4 for the
assessment of unintended medication discrepancies).
The secondary outcome measure of this study is the
proportion of patients with a potential adverse drug
event (pADE) score due to an MTE, both at the moment
of admission and at the moment of discharge. In
addition, the pADEs scores and the associated costs are
secondary outcome measures. A pADE score is defined
as a potential and severity score for discomfort, harm
and/or clinical deterioration caused by an unintentional
discrepancy [19].
Determination of the potential and severity that a
patient will experience harm due to an MTE will be
based on the methodology described by Nesbit et al [19].
The same method was recently used by Gallagher et al
[20]. This method uses the following categories for prob-
ability and severity of harm: 0 (zero; no harm expected
by the MTE), 0.01 (very low: some harm is expected, but
not clinically relevant), 0.1 (low: some harm is expected
but poorly clinically relevant), 0.4 (medium; harm is ex-
pected, clinically relevant) or 0.6 (high; harm is expected,
life threatening). In order to assign the probability and
severity category for each MTE, we will present all
MTEs at ICU admission or discharge to two assessors;
one hospital pharmacist/clinical pharmacologist and one
internist/clinical pharmacologist in training, who will,
independently from each other, make a judgment based
on clinical data of the patient. In case of differences
between the judgments, the assessors will come together
to reach consensus. If consensus cannot be reached, the
case will be presented to a internist/clinical pharmacolo-
gist, who will make the final decision.
Next, our preliminary cost-effectiveness analysis will
estimate the incremental costs per prevented MTE of
the TIM compared to usual care, from the hospital’s
perspective. Costs will comprise both the costs incurred
by the reconciliation process and cost avoidance due to
preventing MTEs and their pADEs.
The cost avoidance of the TIM program will be
determined through summation of the individual pADE
judgment scores of the MTEs and multiplying it by the
cost of an ADE in the pre-intervention period compared
to the post-intervention period.
For measuring the cost of an ADE, we will estimate
the medical consumption associated with the conse-
quences of harm, such as number of ICU days and med-
ical specialist- and nursing staff time, by means of expert
Fig. 3 Study procedure pre- and post-intervention. BPMDL-ICU = best possible ICU medication discharge list, BPMH = best possible medication
history, BPML-GW24 = best possible general ward medication list 24 h after ICU discharge, CPOE/CDS system = computerized physician order
entry systems with clinical decision support, ER = emergency room, HIS = hospital information system, ICU = intensive care unit, OR = operating
room, PDMS = patient data monitoring system, TIM = Transfer ICU and Medication reconciliation program
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opinion and by using previous literature [7, 9, 19–21].
These will be valued using the reference prices of
the ‘Dutch Manual for Costing’ [22]. In case refer-
ence prices are not available, medical consumption
will be valued with the tariffs provided by the Dutch
Healthcare Authority [23]. Costs of potential adverse
drug events will be estimated using previous litera-
ture [6–8, 10].
Costs incurred by the reconciliation process are re-
stricted to labour. The number of minutes spent per
patient by the pharmacist will be measured during the
intervention. These minutes will be valued based on
standardised costs per minute, which equal the norma-
tive income of the pharmacist (collective labour agree-
ment) divided by the number of workable minutes per
year [24].
All costs will be based on Euro cost data. If necessary,
costs will be adjusted to the year of data collection using
the general price index from the Dutch Central Bureau
of Statistics [23].
Data collection
We will screen hospital patient records, PDMS records,
CPOE/CDS medication lists, BPMH and BPML-GW24.
Collected data from these sources will be categorized
into three groups: patient data, medication data and
intervention program data. Data will be collected in case
report forms (CRFs). All data input in the CRF will be
cross-checked by two pharmacists.
Patient data
The following patient data are extracted from the
medical records: age, gender, APACHE II (Acute Physi-
ology and Chronic Health evaluation, score 0–74), SAPS
II (Simplified Acute Physiology Score, scores varying
from 0 to 163 and a predicted mortality rate between 0
and 100%)), reason for the ICU admission, deceased
during the ICU stay, length of ICU stay, specialty of
referring physician, surgical patient or non-surgical
patient, ward from which the patient was referred to the
ICU [emergency room (ER), general ward, OR, cardiac
care unit (CCU), home] and type of admission [planned,
emergency, organ transplantation]. Both APACHE II and
SAPS II are general illness severity scores, APACHE is
the world most widely applied severity of illness score,
whereas SAPS is developed in France and validated in
12 European/North American countries. Both scores are
based on the worst values recorded in the first 24 h of
the ICU stay and are used in the ICU to predict out-
come. They characterize disease severity and degree of
organ dysfunction [25].
Medication data
The following information is collected for all medication
on the BPMH and/or BPML-GW-24: name of medicine,
dose form, medication group, dose and frequency.
We will register for every BPMH medication whether
it is (1) prescribed in the PDMS within 24 h after admis-
sion, (2) registered in the PDMS as “pre-admission
Fig. 4 Flow chart. Assessment of unintended medication discrepancies. BPMH = best possible medication history, ICU = intensive care unit, MTE =
medication transfer error, PDMS = patient data monitoring system
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medication”, (3) prescribed pre-ICU in CPOE/CDS and
(4) registered as “admission medication” in the ICU dis-
charge letter.
We will register for every BPML-GW24 medication
whether it is (1) prescribed in the CPOE/CDS within
24 h after the ICU discharge, (2) in use at discharge
on the ICU according tot the PDMS medication
chart, (3) noted on the PDMS discharge letter as
“ICU medication”.
All discrepancies are scored as intended or non-
intended and finally the discrepancy type: omission,
start, stop, different dose, substitution or incorrect pre-
scribing will be scored.
Intervention program data
During the post-intervention phase the process of medi-
cation reconciliation is qualified as A, B or C. Quality A
is defined as an optimal reconciliation based on a recent,
reliable community pharmacy medication list and a reli-
able verification with patient and/or his representative.
Quality B is defined as an intermediate reconciliation;
the pharmacy record is recent and reliable and screened
for obvious errors, verification with patient or relative is
however not reliable. And finally quality C is defined as
a sub-optimal reconciliation with either the community
pharmacy medication list lacking or the patient/repre-
sentative verification lacking.
Other data collected on medication reconciliation are:
date of reconciliation, within 24 h of the ICU stay or
not, verification with patient and/or representative, time
spent on verification (patient’s interview), the total rec-
onciliation time and finally the number of medications
on the BPMH and BPML-GW24.
Data analysis
Sample size
The primary outcome of this study is the proportion of
patients with one or more transfer errors at admission
to the ICU and at discharge from the ICU.
Based on literature the expected proportion of patients
with medication errors due to transfer between wards
within one hospital is 62% [18]. Based on a conservative
interpretation of this study, it was estimated that this
proportion is 30% in our study. With an estimated 50%
reduction of errors due to the intervention, an alpha of
0.05 and a power of 0.80 the calculated sample size is
133. This sample size is based on patients being alive at
discharge for both the pre-intervention as the post-
intervention phase.
With an estimated mortality of 35%, in each measure-
ment phase 205 patients should be included. Based on
1500 (Haga Teaching Hospital) and 1800 (Erasmus MC)
admissions a year, an estimated loss of 30% due to the
ICU stay less than 24 h and another 35% loss due to
weekend ICU stay, we estimate a study period of 7
weeks for Erasmus MC and 8 weeks for Haga. To be on
the safe side and to measure during a robust interven-
tion period, we will double the number of calculated
weeks. Therefore a pre- and post-intervention period of
14 weeks is chosen.
Statistical analysis
All data will be entered in MS Access 2007 and will be
analyzed with IBM SPSS Statistics 24.
Patients from the intervention and control group will
be compared for all baseline characteristics using t-test
for continuous normally distributed variables, Mann-
Whitney U-test for continuous non-normally distributed
variables and chi square test for categorical variables.
For the primary outcome (MTEs) relative risks and
95% confidence intervals will be calculated. As the study
has a pre- and post-design, results will be corrected for
potential confounders by using multivariate logistic re-
gression analysis.
Subgroup analyses
Since the usual care provided in both hospitals is not
completely the same, the usual care may have impact on
the primary and secondary outcomes, i.e. the number of
MTE and the risk of ADEs. Therefore we will assess in a
secondary analysis, whether the effect of the intervention
is modified by hospital site and we will present subgroup
analyses per site.
Discussion
The aim of this study is to determine the effect of the
TIM program on the proportion of patients with medi-
cation transfer errors (MTEs) at admission to and at dis-
charge from the ICU, and on the number, severity and
cost of potential adverse drug events (pADEs). Although
a randomized controlled trial is generally considered to
be the standard for comparing interventions, unfortu-
nately a randomized design is not feasible for this par-
ticular investigation. Previous experience with similar
projects has demonstrated that usual care is strongly
influenced by an intervention program like TIM, as doc-
tors and other healthcare providers are likely to learn
from the program. Doctors will gain awareness of prob-
lems associated with transfers and may consequently
change their prescribing behavior and the organization
of care.
To be able to compare the effects of TIM with usual
care while avoiding a learning effect, we chose a before
and after design. Although this is conceived to be a weaker
design, we expect this study to have several strengths.
First, pharmacists’ knowledge of the ICU is combined with
pharmacists’ knowledge and skills regarding medication
transfer and medication reconciliation. In both hospitals,
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dedicated ICU pharmacists participated in designing the
TIM program. These ICU pharmacists have a thorough
understanding of the ICU work processes, the ICU
medication issues and the ICU culture. Their medication
transfer and reconciliation skills have been developed in
the previous years during several pilots and studies on
medication transfer and reconciliation in different settings
(admission and discharge from the hospital) [26–28].
Combining all these competencies has led to a robust
design that is tailor-made for both hospitals.
A second strength is that ICU doctors participated in
the final design of the TIM intervention. The TIM study
design was tested from an ICU-doctor perspective dur-
ing a study design meeting with 4 internist-intensivists,
2 from each hospital. This led to some adaptations in
the TIM program and in the outcome measures.
Thirdly, the TIM intervention will be performed by
ICU pharmacists, which will make the cooperation be-
tween pharmacists and the ICU doctors more effective.
The fourth strength of the study is that it is performed
in two different settings, a general teaching hospital and
a university medical center setting, which will provide
stronger results compared to a single site setting.
This study has a number of limitations. First, this
program is performed during workdays but not dur-
ing weekends. This may lead to selection bias because
quality of care can be more compromised in week-
ends than on weekdays due to week/weekend shifts
and limited staff in weekends on the general wards.
Second, the study does not include a hospital setting
in which the PDMS and the CPOE/CDS system are
part of the HIS. An unknown part of our MTEs can
be due to transcription problems between different
prescribing systems, which would not occur in hospi-
tals which only have one prescribing system as part
of the HIS. However, even if only one prescribing
system is used throughout the ICU admission and
discharge, the doctor of the general ward may omit
restarting pre-admission medication after ICU dis-
charge. Be that as it may, this study will not be able
to answer questions about the effect of using two
different prescribing systems as such. Third, although
this study will be performed in two different settings,
results would be even stronger and more generalizable if
more hospitals were included.
Fourth, the study will measure potential adverse drug
events, assessed by a multidisciplinary panel, rather than
actual adverse events. Therefore, in case of positive
results on the primary outcome, future studies will be
needed to study the effect on actual patient harm.
Finally, a period of 14 weeks for the post-intervention
measurement is relatively short; longer periods may be
necessary in order to determine whether the results
remain consistent over time.
While most studies focus on the effect of medication
reconciliation programs at the moment of hospital ad-
mission or discharge, this study focuses on ICU transfers
and will be able to evaluate the clinical and financial
impact of a comprehensive program on continuity of
care. The findings of this study will provide health care
professionals as well as patients, health care managers
and policy makers with valuable information on a crucial
safety intervention in the ICU.
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